Anti-NGF antibodies and methods using same
The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
1. An isolated antibody or fragment thereof comprising
(i) a heavy chain variable region comprising:
(a) a CDR1 region of SEQ ID NO:30;
(b) a CDR2 region of SEQ ID NO:31; and
(c) a CDR3 region selected from the group consisting of SEQ ID NOs.: 11, 56, 58, 60, 62 and 64; and
(ii) a light chain variable region comprising:
(a) a CDR1 region of SEQ ID NO:18;
(b) a CDR2 region of SEQ ID NO: 19; and
(c) a CDR3 region selected from the group consisting of SEQ ID NOs: 14, 57, 59, 61and 63;
wherein the antibody or fragment thereof binds human NGF.
2. An isolated antibody or fragment thereof comprising
(i) a heavy chain variable region comprising:
(a) a CDR1 region of SEQ ID NO:30;
(b) a CDR2 region of SEQ ID NO:31; and
(c) a CDR3 region selected from the group consisting of SEQ ID NOs.: 11, 58, 60, 62 and 64; and
(ii) a light chain variable region comprising:
(a) a CDR1 region of SEQ ID NO:18;
(b) a CDR2 region of SEQ ID NO: 19; and
(c) a CDR3 region selected from the group consisting of SEQ ID NOs: 14, 55, 57, 59, 61, and 63;
wherein the antibody or fragment thereof binds human NGF.
3. The antibody of any of claims 1 , and 2 , wherein the antibody or fragment thereof further binds rodent NGF.
4. The antibody of any of claims 1 , and 2 , wherein the antibody or fragment thereof is a monoclonal antibody.
5. The antibody of any of claims 1 , and 2 , wherein the antibody or fragment thereof is a humanized antibody.
6. The antibody of any of claims 1 , and 2 , wherein the antibody or fragment thereof binds human NGF with a KD of about 2 nM or less.
7. The antibody or fragment thereof of claim 6 , wherein the KD is about 100 pM or less.
8. A pharmaceutical composition comprising (a) the antibody or fragment thereof of any of claims 1 and (b) a pharmaceutically acceptable excipient.
9. A kit comprising the antibody or fragment thereof of any of claims 1 and 8 .
10. A method of making the antibody or fragment thereof of any of claims 1 and 2 , said method comprising expressing a polynucleotide encoding the antibody of any of claims 1 and 2 in a host cell.
11. The antibody of claim 1 , wherein the fragment is Fab, Fab′, F(ab′) 2 , Fv, or single chain (ScFv).
12. The antibody of claim 2 , wherein the fragment is Fab, Fab′, F(ab′) 2 , Fv, or single chain (ScFv).